Oruka Therapeutics Hires Chief Commercial Officer Todd Edwards

What Happened
Oruka Therapeutics announced it has hired Todd Edwards as Chief Commercial Officer under a letter agreement dated July 22, 2026; his employment commenced on August 24, 2026. Edwards, age 63, most recently served in senior commercial roles at Arcutis and previously held leadership positions at Incyte, UCB, AbbVie and TAP Pharmaceuticals. He is a U.S. Army veteran and holds a B.S. in Psychology and an M.B.A.

Key Details

• Base salary: $525,000 annual; eligible for a discretionary bonus targeted at 40% of base salary.
• Up-front compensation: $200,000 signing bonus (payable within 30 days of start, subject to prorated repayment if he leaves or is terminated for cause within the first year).
• Equity grants: stock option for 20,000 shares and RSUs for 100,000 shares. Option vests 25% on Aug 24, 2027, then monthly over the next 36 months; RSUs vest 25% on the first Oruka quarterly vesting date after Aug 24, 2027, then in 12 equal quarterly installments.
• Severance and benefits: if terminated without cause or resigns for good reason, Edwards is eligible for 12 months’ base salary and up to 12 months of Oruka-paid health coverage (with release). If termination occurs within three months before or 12 months after a change in control, severance equals 1.0x (base salary + target bonus), up to 12 months health coverage, and full acceleration of time-based awards plus specified acceleration of performance-based awards. If death or disability, outstanding time-based equity awards fully vest.
• Corporate housekeeping: Edwards entered Oruka’s standard indemnity agreement; there are no family relationships or related-party transactions requiring disclosure.

Why It Matters
This is a material executive hire focused on commercialization: Edwards brings extensive dermatology and immunology commercialization experience, which could help Oruka prepare for product launches or market development. His compensation package ties a significant portion of pay to equity and includes change-in-control protections; investors should note potential future share dilution from option/RSU vesting and the company’s potential cash and benefit costs if severance provisions are triggered.